| 0 (0%) | 11-11 17:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 51.68 |
1-year : | 60.36 |
| Resists | First : | 44.25 |
Second : | 51.68 |
| Pivot price | 41.92 |
|||
| Supports | First : | 40.94 |
Second : | 38.9 |
| MAs | MA(5) : | 41.34 |
MA(20) : | 42.01 |
| MA(100) : | 38.56 |
MA(250) : | 36.58  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 57.3 |
D(3) : | 40.8 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 62.45 | Low : | 23.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AGIO ] has closed below upper band by 13.4%. Bollinger Bands are 1.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 43.91 - 44.08 | 44.08 - 44.25 |
| Low: | 40.73 - 40.92 | 40.92 - 41.12 |
| Close: | 43.53 - 43.84 | 43.84 - 44.16 |
Tue, 11 Nov 2025
What’s next for AGIO stock price - Exit Point & Expert Approved Momentum Ideas - newser.com
Mon, 10 Nov 2025
What the charts say about AGIO today - Market Trend Report & Fast Exit Strategy with Risk Control - newser.com
Sun, 09 Nov 2025
Could Mitapivat Data Shift Agios Pharmaceuticals’ (AGIO) Competitive Edge in Rare Blood Disorders? - simplywall.st
Thu, 06 Nov 2025
Agios Pharmaceuticals (AGIO): Assessing Valuation After Mitapivat’s New Data Brings Pipeline Back Into Focus - simplywall.st
Fri, 31 Oct 2025
Agios Pharmaceuticals (AGIO) Posts $1.1 Billion One-Off Gain, Challenges Earnings Quality Narratives - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | -250 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.81e+007 (%) |
| Held by Institutions | 5.135e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.839e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.28 |
| Profit Margin | 1 % |
| Operating Margin | 590.4 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | 20.1 % |
| Qtrly Rev. Growth | 64 % |
| Gross Profit (p.s.) | 37.86 |
| Sales Per Share | -59.9 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.5628e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 3.88 |
| Price to Sales | -0.74 |
| Price to Cash Flow | 0 |
| Dividend | 4.97e+006 |
| Forward Dividend | 4.74e+006 |
| Dividend Yield | 11331500% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|